Find Academic Supervisors

Michael KutnerView profile

Professor

• Statistical Modeling
• Clinical Trials
• Epidemiology

Michael Kutner is the Rollins Professor of Biostatistics at the Emory School of Public Health, Department of Biostatistics and Bioinformatics. He holds an Endowed Chair and has served in leadership roles, including Chair of the Department of Biostatistics and Bioinformatics (2002-2009) and Chair of the Department of Biostatistics and Epidemiology at the Cleveland Clinic (1994-1999). He has also held roles such as Executive Associate Dean for Faculty Affairs at Emory's School of Public Health (1990-1993). Education: PhD from Texas A&M University, M.S. from Virginia Polytechnic Institute and State University (VPI & SU). His research focuses on Statistical Modeling , Clinical Trials , and Epidemiology . He has contributed extensively to statistical methodology, including works on linear models, regression analysis, and experimental design, with a strong emphasis on applied biostatistics. His publications span foundational textbooks like Applied Linear Statistical Models and Applied Linear Regression Models , which remain influential in statistical education. Recent work includes multi-omic cancer genetics studies and collaborative statistical practices. Awards: ASA Mentoring Award (2018) Lifetime Achievement Awards (ASA Georgia Chapter, 2018) Fellow of the American Statistical Association (1984) H.O. Hartley Award (1984) His career highlights include leadership in academic departments, prolific textbook authorship, and recognition for mentoring and service to the statistical community.

Mark RossView profile

Associate Professor

• Immunology
• Exercise Physiology
• Ageing
• +6 more

Mark Ross is an Associate Professor at Heriot-Watt University, affiliated with the School of Energy, Geoscience, Infrastructure and Society and the Institute for Life and Earth Sciences. He holds roles as Director of Research for the Sport and Exercise Science department and Programme Director for the BSc (Hons) Sport and Exercise Science. He chairs the EGIS Research Ethics Committee and previously served as Programme Leader at Edinburgh Napier University. Education includes a 1st Class Honours Degree in Sport and Exercise Science from Heriot-Watt University (2009, awarded James Watt Medal), an MRes in Exercise Physiology from Waterford Institute of Technology (2011), and a PhD in Exercise Physiology from Edinburgh Napier University (focused on endothelial progenitor cells). His research explores immune cell contributions to inflammation and tissue repair, leveraging exercise as a modulator. Techniques include flow cytometry to study immune cell activation in human samples from exercise studies. Key interests span T-cells, macrophages, aging, and exercise-induced immunological changes. Recent articles highlight work on ultra-endurance exercise's effects on T-cells, vascular aging in centenarians, and exercise-induced progenitor cell mobilization. His studies often integrate clinical, immunological, and physiological perspectives. Awards: James Watt Medal (2009) PhD projects include exercise's role in T-cell-mediated inflammation, immune health in athletes, and exercise in inflammatory conditions. He actively seeks research grants and collaborates on global projects like VascAgeNet. His work contributes to UN SDGs related to health and longevity. Labs/Teams: Active within the Institute for Life and Earth Sciences, collaborating on vascular aging, exercise immunology, and cardiometabolic disease research.

Jennifer GunterView profile

Research Fellow

• Cancer Metabolism
• Prostate Cancer
• Insulin Resistance
• +6 more

Dr. Jennifer Gunter is a Senior Research Fellow at Queensland University of Technology (QUT), affiliated with the Faculty of Health and the School of Biomedical Sciences. Her research focuses on metabolic plasticity in cancer cells, particularly prostate cancer, and the interplay between metabolic disorders and cancer progression. She completed her PhD in 2005 at the University of Oxford, studying lipid metabolism in type-2 diabetes, and has since held postdoctoral positions at the University of Queensland and QUT. Her work integrates metabolomics, cell biology, and clinical translation to identify therapeutic targets. Key areas include insulin resistance, androgen receptor signaling, and drug discovery. Dr. Gunter has secured over $7.9 million in competitive grants and published over 20 peer-reviewed articles, reviews, and book chapters. Her team explores adaptive metabolic pathways in response to therapies like androgen deprivation and biguanides. Dr. Gunter collaborates on projects involving biomaterials (e.g., hydrogel models) and nanoparticle drug delivery. Her research highlights the importance of metabolic reprogramming in treatment resistance and metastasis. She also investigates the role of leptin and cytokines in tumor progression. Future work aims to translate findings into personalized therapies for urological cancers.

Moses S.S. ChowView profile

Professor

• Pharmacotherapy
• Pharmacokinetics
• Cardiovascular Medications
• +4 more

Moses S.S. Chow is a Professor at the College of Pharmacy, Western University of Health Sciences. He holds a PharmD from the University of California, San Francisco (1972), and an AA from the City College of San Francisco (1968). His research spans over five decades, focusing on pharmacotherapy, pharmacokinetics, and drug delivery innovations such as nasal/sublingual formulations. He has pioneered AI integration in healthcare and contributed to prostate cancer treatment strategies. Dr. Chow is a Fellow of the American College of Clinical Pharmacy (FCCP, 1985) and the American College of Clinical Pharmacology (FCP, 1988). Education: AA, 1968, City College of San Francisco PharmD, 1972, University of California, San Francisco His research interests include cardiovascular medications, anticancer treatments, drug delivery systems, and leveraging AI to enhance healthcare. Notably, he served as Director of the Pharmacy School at the Chinese University of Hong Kong and founded the Asian Association of Schools of Pharmacy. Dr. Chow has authored/co-authored over 300 publications, including clinical studies on drug interactions (e.g., Ginkgo Biloba and Omeprazole) and pharmacokinetic modeling. Recent work explores AI’s role in pharmacy practice and personalized prostate cancer therapies via organoid models. Awards: FCCP 1985 (American College of Clinical Pharmacy) FCP 1988 (American College of Clinical Pharmacology) His career highlights include advancing sublingual drug absorption models (e.g., Propranolol) and nasal formulations (e.g., Vardenafil). He has also collaborated internationally, fostering Asian pharmacy education networks through leadership roles.

Ram HariharanView profile

Academic

• AI in Healthcare
• Machine Learning Applications
• Computational Biology
• +3 more

Ram Hariharan is an Associate Teaching Professor and Director of Programs for the College of Engineering and Data Science Faculty at Northeastern University's Seattle campus. He specializes in experiential data science education and AI applications in healthcare, focusing on the intersection of technology, business leadership, and stakeholder collaboration. His work emphasizes real-world case studies and AI-driven solutions for healthcare challenges. Education: PhD in Computational Biology (Statistical Modeling and Simulation of Biophysical Data, Machine Learning), University of Kerala, India (2008) Research Interests: Ram’s research explores AI in healthcare, particularly using machine learning to predict cancer treatment responses, improve wellness for cancer survivors, and democratize access to precision medicine. His projects often involve collaborations with institutions like the Institute for Systems Biology and the University of Washington. Awards and Recognition: British Council Exchange Program award Young Scientist Award from the Government of India Reviewer for grants from the Governments of Poland and Hong Kong Advising and Grants: Ram advises graduate students in AI and data science programs, emphasizing hands-on learning through initiatives like AI Immersion Week. His industry experience includes leading AI teams at MACRO-EYES (now Pendulum Systems) and contributing to AI longevity research via the Artificial Intelligence Longevity Toolbox (AI-LOT) project. Labs and Teams: He collaborates with the Institute for Experiential AI and contributes to interdisciplinary teams at RIKEN (Japan), the University of Oxford, and Singapore’s A* Bioinformatics Institute.

• Surgical Oncology
• Pancreatic Cancer
• Cystic Diseases of the Pancreas
• +4 more

John W. Kunstman, MD, MHS, is an Assistant Professor at Yale University's Department of Surgery, specializing in Surgical Oncology. His clinical focus includes pancreatic, liver, bile duct, stomach, and intestinal cancers or benign diseases. Undergraduate: University of Wisconsin (with honors) Medical School: University of Wisconsin School of Medicine and Public Health Residency: Yale-New Haven Hospital (General Surgery) Fellowship: Memorial Sloan Kettering Cancer Center (Complex General Surgical Oncology) Master's Degree: Yale University Dr. Kunstman's research bridges early detection of pancreatic precursor lesions with clinical outcomes post-pancreatic surgery. He leads studies on single-cell markers for intraductal papillary mucinous neoplasms progression and cyst-forming phenotype genetics. His clinical research revolutionized Whipple procedure practices by reducing nasogastric decompression and improving drain management through multi-institutional collaborations. Recent publications address peritoneal metastases from neuroendocrine tumors, gastric neuroendocrine neoplasms management, and postoperative mortality factors in pancreatic adenocarcinoma. His work explores surgical outcomes optimization, perioperative electronic consultation models, and pandemic impacts on GI cancer care. Dr. Kunstman maintains active membership in the Society of Surgical Oncology and American College of Surgeons, with recognition for teaching, research, and clinical excellence. Samuel Harvey Award for Outstanding Performance as Chief Resident Dennis Wasson Award for Surgical Residency Excellence Resident of the Year for Basic Science Research Ira S. Goldenberg Award for First-Year Residency

• CRISPR Technology
• Immunotherapy
• Cancer Research
• +3 more

Xiao Zhou is a Research Fellow at the Yale School of Medicine, where he focuses on advancing CRISPR-based technologies, immunotherapy, and cancer research. He holds a PhD from Boston University (2022) and contributes to interdisciplinary studies at the intersection of genetics, immunology, and virology. His work emphasizes multiplexed gene editing in immune cells, tumor immunology, and vaccine development against pathogens like SARS-CoV-2. Research Interests: Dr. Zhou’s research explores CRISPR applications in cellular engineering, immunotherapy strategies for cancer resistance, and the design of variant-specific vaccines. His studies often involve in vivo CRISPR screens to uncover therapeutic targets in CD8 T cells and regulatory T cell dynamics. Publications: His work spans CRISPR-mediated genome editing, CAR-T cell enhancements, and heterotypic vaccine responses. Recent studies highlight breakthroughs in Cas12a knock-in mice models and mechanisms of tumor immunity. Professional Background: As a Research Fellow, Zhou collaborates with teams advancing translational medicine and viral immunology. His contributions bridge basic science and clinical applications, with a focus on precision interventions in oncology and infectious diseases.

• Health Policy
• Genomics
• Pharmacogenomics
• +4 more

Professor Christine Lu is a globally recognized academic in clinical pharmacy and pharmacoeconomics, serving as Chair of Clinical Pharmacy at the Sydney Pharmacy School, University of Sydney. She holds a dual appointment at the Northern Sydney Local Health District and has held previous roles at Harvard Medical School and Harvard Pilgrim Health Care Institute. Her expertise spans health policy, genomic medicine, and pharmacoepidemiology, with a focus on optimizing medication use and outcomes in diverse populations. Education & Career: Dr. Lu earned her MSc (Biopharmaceuticals) and PhD from the University of New South Wales and completed postdoctoral training at Harvard Medical School. She transitioned from academic roles in the U.S. to the University of Sydney in 2023. Research Interests: Her work addresses critical issues in healthcare systems, including: Impact of health policies on medication access and outcomes Genomic healthcare (e.g., pharmacogenomics) and ethical implications Quality use of high-cost medicines and biosimilars Real-world evidence generation using linked datasets Her current projects include national analyses of precision medicine and biosimilar utilization in Australia. Publications & Impact: Over 200 peer-reviewed articles reflect her focus on disparities in chronic disease outcomes, pharmacogenetic testing, and AI-driven predictive analytics. Recent work highlights disparities in heart failure mortality among diabetes patients and the utility of genomic testing in pediatric populations. Awards & Recognition: Recipient of the Genomic Innovator Award (NIH, 2020-2025), Robert H. Ebert Career Development Award (Harvard, 2018-2020), and the Caroline Miles Award (University of Oxford, 2016). Grants & Mentorship: Leads postgraduate research scholarships in medicines policy and outcomes research. Current advisees include Harry LE (optimizing psychotropic use in dementia) and Benson YIU (biosimilar utilization analysis). She chairs multidisciplinary teams at the Sydney Pharmacy School and collaborates internationally on implementation science initiatives like the IMPULSS program for Lynch syndrome screening. Labs & Collaborations: Active in translational research through the Sydney Pharmacy School’s Clinical Pharmacy Unit, focusing on real-world data applications and health technology assessment. Collaborates with global networks including ISPOR and the Harvard Club of Australia.

Zoë WaltersView profile

Associate Professor

• Epigenetics and Genomics
• Cancer Biology
• Target Prioritisation and Validation
• +3 more

Dr. Zoë Walters is an Associate Professor in Translational Epigenomics at the University of Southampton, affiliated with the Faculty of Medicine and Cancer Sciences department. She leads the MSc Genomics program's Genomics Guided Treatment and Dissertation modules and contributes to BMedSci teaching. Her research focuses on epigenetic mechanisms in cancer and developmental disorders, particularly targeting therapies for pediatric cancers like neuroblastoma and rhabdomyosarcoma. She collaborates on projects addressing therapy resistance, tumor microenvironment dynamics, and precision medicine approaches. Current research includes investigating EZH2 inhibitors in combination therapies, leveraging omic data for sarcoma treatment, and understanding mechanisms of therapeutic resistance. She has received awards such as the Norman Williams Prize (2024) and Young Investigator Award (2023). Her lab also explores AI applications in clinical decision-making for oesophageal cancer. Zoë has supervised numerous PhD students and contributed to over 10 peer-reviewed publications. She serves on editorial boards (e.g., Frontiers in Cell and Developmental Biology) and reviews for journals like Nature Communications and Clinical Epigenetics. Her work spans interdisciplinary collaborations, including with engineering and computer science teams for AI-driven oncology solutions.

Yuanyuan GuView profile

Associate Professor

• Health Economics
• Economics of Ageing
• Choice Modelling
• +7 more

Yuanyuan Gu is an Associate Professor at Macquarie University's Centre for the Health Economy. His expertise spans health economics, aging, choice modeling, and econometrics, with a focus on preferences and decision-making in healthcare systems. He leads the health preference research stream and advises on health technology assessments. He has secured over A$14 million in funding, including a Marie Skłodowska-Curie Fellowship. Education: PhD in Economics (UNSW, 2011), MCom (Hons) in Economics (UNSW), BSc in Statistics (Fudan University). Research Interests include improving healthcare quality through preference analysis, cost-effectiveness studies, and policy-relevant research. Recent projects address aged care financing, patient preferences for treatments, and precision medicine applications. Key Awards: MQBS Research Impact Prize (2023, 2025), Centre for Health Economy Publication Prize (2023). Advising & Grants: Supervises 6 current PhD students (e.g., Zobaida Ahmed Piu on oral contraceptives, Han Cheng on income inequality and health) and advises on PBAC evaluations. Active in editorial roles for PharmacoEconomics and Journal of Hospital Management and Health Policy . Labs/Teams: Collaborates on projects like sensory support interventions for dementia patients and outcomes-based care evaluations for vulnerable populations.

• Cancer
• Clinical Trials
• Cardiovascular Disease
• +3 more

Professor John Simes AO is a Professor of Clinical Epidemiology at the University of Sydney's Faculty of Medicine and holds leadership roles at the NHMRC Clinical Trials Centre (CTC), including Senior Associate Director and Co-Director of Cancer Trials. He has led over 100 multicenter clinical trials, notably the LIPID and FIELD trials, contributing to global guidelines in cardiovascular and diabetes care. His research spans cancer, cardiovascular disease, neonatal medicine, and clinical trial methodology. Education: BSc (Med), MBBS, FRACP, SM (Harvard), MD. He is a practicing Medical Oncologist at Royal Prince Alfred Hospital and Chris O'Brien Lifehouse. Research Interests: Large-scale clinical trials in oncology (e.g., gastrointestinal, genitourinary cancers), cardiovascular risk reduction, and neonatal medicine. Notable contributions include demonstrating pravastatin's survival benefits (LIPID trial) and fenofibrate's microvascular benefits (FIELD trial). Current trials include INTEGRATE (gastric cancer) and INSPIRE (aspirin in VTE). Awards: Order of Australia (2020), MOGA Cancer Achievement Award (2010), Harvard Biostatistics Alum Award (2009), and R.T. Hall Prize (1999). Advising: Supervises students like Janene Dalrymple on translational research. Grants: Holder of NHMRC Senior Principal Research Fellowship and Program Grants. Labs/Teams: Leads CTC's oncology trials group and chairs INSPIRE Steering Committee.

• Pharmacogenomics
• Pharmacist-led interventions
• Pharmacy education
• +5 more

Dr. Chiao Xin Lim is a Senior Lecturer in the Department of Health and Biomedical Sciences at RMIT University. Her research focuses on pharmacogenomics implementation, culturally competent healthcare interventions, digital health innovation, and pharmacy education. She coordinates third-year undergraduate pharmacy practice courses and supervises research projects addressing medication adherence in culturally diverse populations. Professional roles include General Council member and Education Representative for the Australasian Pharmaceutical Science Association (2023-24) and membership in the Pharmaceutical Society of Australia. Key research interests span asthma self-management in Middle Eastern Arabic-speaking refugees, palliative care pharmacist roles, and educational strategies for cultural competence in health professions. Dr. Lim's teaching innovations include case-based learning for cultural competence and interprofessional simulations between nursing/pharmacy students. She has pioneered validated tools for asthma inhaler technique assessment in Arabic-speaking populations and developed survey instruments for oncology pharmacogenomics education needs. Supervision Focus: Culturally responsive healthcare strategies for cardiovascular, diabetes, and respiratory conditions Key Projects: Pharmacogenomics implementation in oncology, digital health interventions for medication adherence, and policy analysis for asylum seeker health equity Labs/Teams: Actively involved in multidisciplinary research teams addressing healthcare disparities and pharmacist-led interventions. Collaborates with international partners on translational research projects.

Carsten Dahl MørchView profile

Associate Professor

• Diabetic Neuropathy
• Peripheral Neuropathy
• Pain Perception
• +5 more

Carsten Dahl Mørch is an Associate Professor at the Department of Health Science and Technology, Faculty of Medicine, Aalborg University. He leads the Cutaneous Pain Research Laboratory and is affiliated with the Center for Sensory-Motor Interaction and the Translational Pain Neuroscience and Precision Health Center. His research focuses on pain mechanisms, diabetic neuropathy, peripheral nerve function, and neuroplasticity. He holds a Ph.D. in Biophysics and an M.Sc. in Biophysics. Education: Ph.D. in Biophysics (2006) M.Sc. in Biophysics (2002) Research Interests: Diagnosis of small fiber neuropathy Experimental methods for studying hyperalgesia Digitalization of human neuroscience Pain perception complexity Neuropathic pain in diabetes Key Projects: Diabetic Peripheral Neuropathy: Early detection and severity grading (2018–present) Computational modeling of peripheral nerves (2017–present) Assessment of oxaliplatin-induced peripheral neuropathy (2014–present) Labs/Teams: Cutaneous Pain Research Laboratory Center for Neuroplasticity and Pain

Katarzyna BozekView profile

Professor

• Deep Learning
• Computational Biology
• Medical Image Analysis
• +8 more

Katarzyna Bozek is a Professor at the University of Cologne and leads the Bozek Lab at the Center for Molecular Medicine Cologne. Her research focuses on developing deep learning methods for quantitative analysis of biomedical image and time series data, with applications in pathology, nephrology, neurology, and cancer research . Collaborations include institutions like the University Hospital Cologne. Research areas: Computational Biology & Medicine, Machine Learning, Biomedical Image Analysis Key projects: Explainable AI for histopathology data, DISK model for behavioral science The lab applies novel computer vision techniques to C. elegans behavior analysis and super-resolution microscopy in kidney research. Recent work includes transformers pretrained on text for Whole Slide Image classification and federated learning models for precision oncology. Advising : Supervised doctoral candidates including Juan Pisula, Maurice Deserno, and Hussein Naji . The lab actively collaborates on interdisciplinary projects, with funding from multiple partners.

Devika ChithraniView profile

Professor

• Nanotechnology
• Cancer Nanomedicine
• Radiosensitizers
• +6 more

Devika Chithrani is Professor in the Department of Physics and Astronomy at the University of Victoria's Faculty of Science, leading pioneering research in cancer nanomedicine using gold nanoparticles to enhance radiotherapy and chemotherapy while reducing normal tissue toxicity. Education: PhD, University of Toronto, Canada MSc, University of Toronto, Canada BSc (Hons), University of Colombo, Sri Lanka NSERC Postdoctoral Fellow, University of Toronto, Canada Her research focuses on nanoparticle synthesis/characterization, radiosensitizer development, and multimodal imaging systems. She investigates how nanoparticle size, shape, and surface properties dictate intracellular fate in vitro and in vivo, engineering 3D tissue-like models to optimize therapeutic platforms. Her work bridges fundamental bio-nano interface studies with clinical translation for improved cancer diagnostics and treatment. Publication trends from 2006-2022 reveal progression from foundational nanoparticle-cell interaction studies to advanced tumor microenvironment applications and combination therapies (e.g., gold nanoparticles with pyronaridine/bleomycin), demonstrating translational momentum toward clinical implementation in radiation oncology. Scientific awards: NSERC Postdoctoral Fellow She mentors 5 current graduate students (including NSERC-funded PhD candidates Nolan Jackson and Daniel Cecchi) and has supervised 10+ previous students who received prestigious awards like NSERC CGS D and UVic Fellowships. Her research is funded by CIHR, NSERC, Mitacs Accelerate, CFI, BCKDF, and the Government of Canada's NCE Program. She directs the Nanoscience and Technology Laboratory, a multidisciplinary team integrating physics, chemistry, biology, and computer science to develop nanomaterials (gold/lipid nanoparticles) that enhance radiotherapy/chemotherapy efficacy through precise tumor targeting and reduced systemic toxicity.